证券代码：837344 证券简称：三元基因 公告编号：2023-004 北京三元基因药业股份有限公司 持股 5%以上股东减持股份计划公告（再次披露） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 减持主体的基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 浙江圣达 | 持股 | 5%以 | 14,720,255 | 12.0846% | 进入北交所前取得 | | 科技发展 | 上股东 | | | | | | 有限公司 | | | | | | 二、 减持计划的主要内容 | | | | | | 减持 | 拟减 | 拟减 | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 计划减持数量 | 计划减持比 | 减持 | 减持 | | 持股 | | | 名称 | （股） | 例 | 方式 | 期间 | 价格 | ...

Financial Performance - The company's operating revenue for 2022 was CNY 170,998,937.09, a decrease of 15.18% compared to CNY 201,604,942.27 in the previous year[4] - The net profit attributable to shareholders was CNY 31,789,003.35, down 21.34% from CNY 40,414,576.19 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,561,129.55, a decrease of 6.85% compared to CNY 32,809,891.49 in the previous year[4] - Basic earnings per share were CNY 0.26, down 21.21% from CNY 0.33 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 930,362,961.14, an increase of 43.07% from CNY 650,273,778.58 at the beginning of the period[5] - Shareholders' equity attributable to the company was CNY 575,543,886.95, up 5.96% from CNY 543,170,952.35 at the beginning of the period[5] Impact of Pandemic - The decrease in revenue and net profit was primarily due to the impact of the pandemic, which led to a significant reduction in patient visits to hospitals[6] - The company expects sales to gradually improve following the relaxation of pandemic policies in December, although overall revenue for the year still declined compared to the previous year[8] Future Outlook and Notes - The growth in total assets was mainly driven by the advancement of the intelligent production base project for gene engineering drugs and R&D fundraising projects[8] - Investors are advised to note that the financial data for 2022 is preliminary and subject to audit, which may result in discrepancies[9]

证券代码：837344 证券简称：三元基因 公告编号：2023-002 北京三元基因药业股份有限公司 持股 5%以上股东减持股份计划公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 二、 减持计划的主要内容 | 股东 | 计划减持数量 | 计划减持比 | 减持 | 减持 | 减持 | 拟减持 | 拟减持 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 价格 | 股份来 | | | 名称 | （股） | 例 | 方式 | 期间 | 区间 | 源 | 原因 | | 浙江 | （3,600,000） | （2.9554%） | 集中 | 自公 | 市场 | 进入北 | 自身经 | | 圣达 | | | 竞价、 | 告之 | 价格 | 交所前 | 营需要 | | 科技 | | | 大宗 | 日起 | | 取得 | | | 发展 | | | 交易 | 30 | | | | （二） 相关股东是否有其他安排 □是 √否 （三） 股东此 ...

北京三元基因药业股份有限公司 2022 年股权激励计划股票期权授予结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 重要内容提示： 根据中国证监会《上市公司股权激励管理办法》、北京证券交易 所、中国证券登记结算有限责任公司北京分公司有关规则的规定，北 京三元基因药业股份有限公司（以下简称"公司"）完成了本次股票 期权授予登记工作，有关具体情况公告如下： 一、股票期权授予结果 （一）实际授予基本情况 1、期权简称：三元 JLC1，期权代码：850053 证券代码：837344 证券简称：三元基因 公告编号：2023-001 注：数据部分系合计数与各加总数直接相加之和在尾数上可能略有差 异，系四舍五入造成，并非计算错误。 本次登记完成股票期权名单如下： | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 晏征宇 | 董事 | | 2 | 王冰冰 | 董事会秘书、副总经理 | | 3 | 张凤琴 | 财务总监、副总经理 | 3、登记日：2023 年 1 月 5 日 4 ...

Financial Performance - In the first half of 2022, the company achieved operating revenue of 64.36 million yuan and a net profit of 5.93 million yuan, with a product gross margin of 80.08%[8] - The company's revenue for the reporting period was ¥64,357,584.88, a decrease of 13.42% compared to ¥74,331,152.94 in the same period last year[30] - The net profit attributable to shareholders was ¥5,931,728.13, reflecting a decline of 35.91% from ¥9,255,803.84 year-on-year[30] - The gross profit margin decreased to 80.08% from 81.61% in the previous year[30] - Basic earnings per share fell by 37.50% to ¥0.05 from ¥0.08 in the same period last year[30] - The weighted average return on net assets based on net profit attributable to shareholders was 1.09%, down from 1.75%[30] - The company reported a net profit of ¥4,945,987.42 after deducting non-recurring gains and losses, a slight increase of 1.24% from ¥4,885,631.81[30] - Net profit decreased by 35.91%, reflecting ongoing challenges in profitability[33] Assets and Liabilities - Total assets increased by 4.68% to ¥680,689,214.20 compared to the previous year[31] - Total liabilities rose by 22.86% to ¥131,586,533.72, indicating increased financial leverage[31] - The company's total assets at the end of the period amounted to 680,000,000.00 CNY, with cash and cash equivalents decreasing by 19.46% to 220,863,325.02 CNY[62] - Accounts receivable decreased by 23.10% to 69,721,550.44 CNY, while prepayments increased significantly by 335.56% to 14,298,857.85 CNY due to enhanced market promotion efforts[63] - Inventory increased by 32.22% to 26,899,145.49 CNY, attributed to strategic raw material reserves and domestic sourcing adjustments[64] - Total liabilities reached CNY 130,089,254.91, up from CNY 106,268,831.41, indicating a growth of 22.4%[145] Research and Development - The company emphasizes the importance of R&D and academic promotion in its strategic direction to maintain competitive advantages in the biopharmaceutical industry[7] - The company has established four major technology platforms to support ongoing innovation and development[42] - The company is pioneering clinical research on human interferon α1b for respiratory syncytial virus pneumonia and COVID-19[40] - The company has successfully developed a unique water injection formulation for human interferon α1b, enhancing its product stability[41] - The company is advancing four new drug development projects, including a Phase III clinical trial for inhaled interferon α1b for pediatric RSV pneumonia[49] - The company is also conducting a Phase III clinical trial for interferon α1b in treating COVID-19, with ongoing studies in both mainland China and Hong Kong[50] - The company has ongoing significant research and development expenditures related to clinical trials for interferon α1b, which are progressing smoothly[174] Market Position and Strategy - The company is focusing on a development path characterized by specialization, refinement, uniqueness, and innovation, aiming to become a high-quality development "specialized and innovative" enterprise[7] - The company’s main product, human interferon α1b, has a significant contribution to revenue, and the market demand for this product remains high due to its confirmed efficacy and broad clinical application[13] - The product "Yundesu®" (human interferon α1b) has a leading market share in China's interferon market[37] - The company is actively exploring new market segments for its main product, human interferon α1b, to meet the growing clinical demand[96] - The company has a comprehensive strategy to address market expansion risks by leveraging its brand value and focusing on differentiated product promotion[97] Financial Management - The company has signed a fixed asset loan agreement with a total amount of 470 million yuan, with a repayment period of 15 years, secured by land use rights and construction projects[14] - The company has a long-term loan repayment schedule, with a total outstanding balance of ¥65,503,495.98 as of the reporting period, which is manageable within its financial capabilities[100] - The company has implemented measures to mitigate accounts receivable risks, including strengthening management of drug distribution companies and establishing credit control systems[93] - The company has a robust internal control system to manage credit risks associated with its accounts receivable[93] Regulatory and Compliance - The company has secured 12 drug registration certificates, demonstrating compliance with stringent regulatory standards in the biopharmaceutical industry[45] - The company is committed to environmental protection, ensuring compliance with environmental laws and maintaining a robust environmental management system[88] - The company has received approval for the environmental impact report for the gene engineering drug production base project from the Beijing Daxing District Ecological Environment Bureau[89] Shareholder Information - The total share capital of the company is 121,810,000 shares[24] - The controlling shareholder is Beijing Southeast Pharmaceutical Investment Holding Co., Ltd.[25] - The largest shareholder, Beijing Southeast Medicine Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of total shares[116] - The company’s total share capital remains at 121,810,000 shares, with 7,517 shareholders reported[113] Economic Environment - The pharmaceutical industry in China is experiencing growth due to increasing healthcare demands driven by an aging population and rising health awareness[55] - The government is actively supporting the biopharmaceutical industry, aiming to transition China from a major pharmaceutical country to a strong pharmaceutical country by 2030[57] - The macroeconomic environment for the pharmaceutical industry remains complex, with pressures from healthcare expenditure and policy reforms impacting operations[56] - The company aims to leverage the strategic opportunities presented by the government's support for the biopharmaceutical sector to enhance its market position[61]

Financial Performance - Operating revenue for the first quarter of 2022 was CNY 29,687,302.57, down 13.12% year-on-year[16] - Net profit attributable to shareholders for the first quarter of 2022 was CNY 3,351,979.41, an increase of 18.72% compared to the same period last year[16] - Basic earnings per share for the first quarter of 2022 were CNY 0.03, up 50.00% from CNY 0.02 in the previous year[16] - Total operating revenue for Q1 2022 was ¥29,687,302.57, a decrease of 13.5% from ¥34,171,109.14 in Q1 2021[43] - Net profit for Q1 2022 increased to ¥3,351,979.41, representing a growth of 18.7% compared to ¥2,823,376.49 in Q1 2021[45] - Operating profit for Q1 2022 was ¥3,908,239.93, an increase from ¥3,238,899.40 in Q1 2021[44] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 633,768,796.90, a decrease of 2.54% compared to the end of the previous year[16] - The company's total liabilities to total assets ratio was 13.77% as of March 31, 2022, down from 16.47% at the end of the previous year[16] - Total liabilities decreased to CNY 87,245,865.14 from CNY 107,102,826.23, a reduction of 18.6%[37] - Total equity increased to CNY 546,522,931.76, up from CNY 543,170,952.35, reflecting a growth of 0.6%[37] - The total assets decreased to ¥655,806,914.15 from ¥671,514,340.21[41] - Total liabilities decreased to ¥87,239,467.94 in the latest reporting period, down from ¥106,268,831.41[41] Cash Flow - Net cash flow from operating activities increased by CNY 17,055,940.04, representing a growth of 592.80% compared to the previous year[17] - Cash inflows from operating activities reached CNY 56,961,110.72, up from CNY 42,777,401.41 year-over-year[50] - The net cash flow from operating activities was CNY 14,178,778.03, a recovery from a negative CNY 2,877,162.01 in the previous year[52] - The company reported a net cash outflow from financing activities of CNY 1,233,195.61, an improvement from negative CNY 7,546,414.36 last year[52] - The company experienced a net decrease in cash and cash equivalents of CNY 28,713,615.61, compared to a decrease of CNY 19,798,432.64 in the previous year[55] Shareholder Information - The registered capital of the company is CNY 121,810,000[14] - The total number of ordinary shareholders is 7,623[20] - The largest shareholder, Beijing Southeast Medicine Investment Holding Co., Ltd., holds 46,907,925 shares, representing 38.51% of total shares[22] - Zhejiang Shengda Technology Development Co., Ltd. is the second largest shareholder with 17,199,373 shares, accounting for 14.12%[22] - The total shares held by the top ten shareholders amount to 90,000,950, which is 73.89% of the total shares[22] Research and Development - The company is conducting a Phase III clinical trial for a drug targeting respiratory syncytial virus, with 190 subjects enrolled as of January 18, 2022[31] - The company has completed the first interim analysis of the clinical trial, with positive efficacy trends and good safety observed[31] - Research and development expenses decreased to ¥2,123,768.92 in Q1 2022, down 53.8% from ¥4,592,697.23 in Q1 2021[44] Compliance and Commitments - The company has complied with all commitments made during its public offering process, with no breaches reported[27] - The company has no ongoing litigation, external guarantees, or external loans during the reporting period[26] - The company has no profit distribution or capital increase from reserves during the reporting period[32] Asset Management - The company has pledged assets totaling 76,309,892.76 yuan, which represents 12.04% of total assets[29] - Current assets totaled CNY 360,672,150.71, a decrease of 10.5% from CNY 403,029,145.30 as of December 31, 2021[35] - Accounts receivable decreased to CNY 74,656,756.47 from CNY 90,665,072.86, representing a decline of 17.7%[35] - Inventory increased to CNY 25,894,154.27, up 27.0% from CNY 20,343,948.52[35] - Total non-current assets rose to CNY 273,096,646.19, an increase of 10.4% from CNY 247,244,633.28[36] - Cash and cash equivalents were CNY 245,884,230.48, down from CNY 274,215,710.45, a decrease of 10.3%[35]

Financial Performance - In 2021, the company achieved a revenue of 202 million RMB, with a net profit of 40.41 million RMB, representing a year-on-year growth of 12.38%[6] - The company's operating revenue for 2021 was CNY 201,604,942.27, representing a year-over-year increase of 9.67% compared to CNY 183,827,367.90 in 2020[35] - The net profit attributable to shareholders for 2021 was CNY 40,414,576.19, which is a 12.38% increase from CNY 35,963,788.73 in 2020[35] - The gross profit margin for 2021 was 81.01%, down from 84.00% in 2020[35] - The company's total revenue for the current period reached ¥201,604,942.27, representing a 9.67% increase compared to ¥183,827,367.90 in the same period last year[90] - The company's main business revenue reached ¥201,603,579.43, representing a year-on-year increase of 9.69%[95] Research and Development - The company is focused on developing new products, including a novel PEG-integrated interferon mutant injection, which aims to combine long-lasting effects with high efficacy and safety[22] - The company has established four key technology platforms, including a high stability protein solution technology platform and a novel interferon preparation technology platform, which have received multiple patents in China, the US, Japan, and South Korea[57] - The company is advancing the "γδT cell tumor immunotherapy clinical research" project and related product development, integrating the cell therapy industrialization platform into the construction of a new intelligent factory[72] - The company is actively developing new products, including nebulized inhalation formulations and PEG modification technologies, which are at the international leading level[150] - The company is conducting Phase III clinical trials for human interferon α1b for the treatment of RSV pneumonia in children, with over 80% of enrollment targets achieved across 28 clinical research centers[118] Market Position and Strategy - The company primarily engages in the research, development, production, and sales of biopharmaceuticals, with key products including interferon α1b formulations[28] - The company has developed a clear profit model primarily through the sales of human interferon α1b, which has maintained a leading market share in China's interferon market for several consecutive years[53] - The company is actively pursuing market expansion strategies to diversify its revenue streams and reduce dependency on a single product line[163] - The company is focusing on continuous innovation and brand enhancement, with four new drug R&D projects progressing well, positioning it for broader market opportunities[162] Financial Management - The company's cash flow from operating activities decreased by 39.40% to CNY 42,745,631.37 in 2021, down from CNY 70,535,446.29 in 2020[39] - The total assets increased by 10.43% to CNY 650,273,778.58 at the end of 2021, compared to CNY 588,864,751.51 at the beginning of the year[37] - Total liabilities rose significantly by 79.84% to CNY 107,102,826.23 at the end of 2021, compared to CNY 59,553,795.37 at the beginning of the year[37] - The company's asset-liability ratio (consolidated) was 16.47% at the end of 2021, up from 10.11% at the beginning of the year[37] Regulatory and Industry Environment - The pharmaceutical industry is highly regulated in China, with significant risks associated with policy changes that could impact operational strategies and market demands[17] - The National Healthcare Security Administration initiated a bulk procurement policy for insulin, expanding it to biological drugs, which may lead to significant price reductions and increased operational challenges for companies[17] - The pharmaceutical industry is expected to grow due to increasing healthcare demands driven by an aging population and enhanced health awareness[147] Corporate Governance and Social Responsibility - The company emphasizes the importance of ESG principles, focusing on environmental protection, social responsibility, and governance, particularly after its listing on the Beijing Stock Exchange in November 2021[136] - The company has established a robust governance structure, adhering to laws and regulations, and has committed to enhancing its internal control systems following its listing on the Beijing Stock Exchange[142] - The company has been recognized for its leadership in poverty alleviation efforts, with its chairman awarded for outstanding contributions in this area[134] Intellectual Property and Innovation - The company holds a total of 52 patents, including 49 invention patents, maintaining its focus on innovation and development in biotechnology[122] - The company emphasizes the importance of intellectual property protection, with a high percentage of its patents valued above 8 points, indicating strong patent value in the antiviral drug sector[58] - The company has obtained invention patent authorization for key technologies involved in its hepatitis treatment products, positioning itself at an industry-leading level[128] Clinical Trials and Product Development - The company has initiated a Phase III clinical trial for the nebulized inhalation treatment of pediatric RSV pneumonia, achieving 80% enrollment completion across 28 clinical research centers[60] - The company is also conducting a Phase III clinical trial for the treatment of COVID-19 pneumonia, collaborating with five designated treatment centers and adapting the trial protocol based on the evolving characteristics of the virus[61] - The company has successfully designed an adaptive clinical trial protocol for the new PEG-integrated interferon mutant injection for hepatitis B, with plans to conduct trials at 15 clinical centers nationwide[71] Shareholder and Equity Information - The total number of ordinary shares outstanding is 121,810,000, indicating a substantial equity base for the company[29] - The controlling shareholder is Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., with actual controllers being Cheng Yongqing, Yin Xiaoming, and Cheng Shiqing[29] - The company declared a cash dividend of CNY 2.18 per 10 shares on May 21, 2021, with no stock bonus or capital increase[198]